In Vitro Activities of Omadacycline and Comparators against Anaerobic Bacteria-Reference-Cited by-同舟云学术

In Vitro Activities of Omadacycline and Comparators against Anaerobic Bacteria

Published:2018-04 Issue:4 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Stapert Laure¹,Wolfe Cindy¹,Shinabarger Dean¹,Marra Andrea¹,Pillar Chris¹

Affiliation:

1. Micromyx, Inc., Kalamazoo, Michigan, USA

Abstract

ABSTRACT Omadacycline (OMC), a broad-spectrum aminomethylcycline, has shown clinical efficacy in anaerobic acute bacterial skin and skin structure infections (ABSSSI) and in animal models of intra-abdominal anaerobic infections. Here, the in vitro activity of OMC against clinically relevant anaerobes was similar to that of tigecycline, with MIC 90 values of 1 to 8 μg/ml against Bacteroides spp., 0.5 μg/ml against Clostridium difficile , Prevotella spp., and Porphyromonas asaccharolytica , 1 μg/ml against Peptostreptococcus spp., and 16 μg/ml against Clostridium perfringens .

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00047-18

Reference8 articles.

1. Spectrum and treatment of anaerobic infections

2. Tzianabos AO, Kasper DL. 2005. Anaerobic infections: general concepts, p 2810–2816. In Mandell GL, Bennett JE, Dolin R (ed), Principles and practice of infectious disease, 6th ed. Elsevier Saunders, Philadelphia, PA.

3. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections

4. O'Riordan W, Green S, Overcash JS, Eckburg P, Steenburgen J, Das A, Tzanis E, Garrity-Ryan L, Manley A, Villano S, Loh E. 2017. Efficacy of oral and IV omadacycline vs. linezolid for treating adult subjects with ABSSSI: analysis by infection type and pathogen in the oasis study. Poster presentation P1252. European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria.

5. Endermann R, Ladel CH, Broetz-Oesterhelt H, Labischinski H. 2004. BAY 73-7388 is highly efficacious in animal models of intra-abdominal infections caused by a range of aerobic and anaerobic organisms, including VRE. Poster P928. European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic.

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review of Omadacycline for Potential Utility in the Military Health System for the Treatment of Wound Infections;Military Medicine;2023-10-31

2. New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians;Pharmaceuticals;2023-09-15

3. Antimicrobial susceptibility of Clostridioides difficile to omadacycline and comparator antimicrobials;Journal of Antimicrobial Chemotherapy;2023-06-06

4. Review of Novel Third-Generation Tetracyclines: Eravacycline, Omadacycline, and Sarecycline;Clinical Microbiology Newsletter;2023-04

5. Omadacycline in treating community-based infections: a review and expert perspective;Expert Review of Anti-infective Therapy;2023-02-06